1.
J Am Acad Dermatol
; 84(4): e197-e198, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1139510
Subject(s)
COVID-19 , Pemphigus , COVID-19 Vaccines , Humans , Immunologic Factors , Pandemics , Pemphigus/drug therapy , Pemphigus/epidemiology , Rituximab/therapeutic use , SARS-CoV-2
2.
Mult Scler Relat Disord
; 44: 102199, 2020 Sep.
Article
in English
| MEDLINE | ID: covidwho-306240
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2, which affects the lung and other organs. After an incubation period of 3-14 days, the infection presents with symptoms of variable severity, from mild flu-like disease to severe pneumonia and cytokine storm with increased mortality. Immunosuppressed patients may have higher risk of adverse outcomes; hence, there is an urgent need to evaluate the immune response and clinical outcomes of SARS-CoV-2 infection in these patients. Here, we report a 59-year-old woman with aquaporin-4-positive (AQPR4+) neuromyelitis Optica treated with rituximab who developed mild respiratory symptoms with COVID-19, despite B cell depletion at the time of infection.